Compare Advance Auto Parts, Inc. (AAP) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Gilead Sciences, Inc. — how do they compare? Advance Auto Parts, Inc. trades at $54.83 (market cap $3.37B), while Gilead Sciences, Inc. trades at $135.43 (market cap $169.30B). The key difference: Gilead Sciences, Inc. is far larger — about 50.2× Advance Auto Parts, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.41%). Which is the better fit depends on your goals.
| AAP | GILD | |
|---|---|---|
Market Cap | $3.37B | $169.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $66.50 | $155.80 |
52-Week Low | $38.75 | $108.22 |
Enterprise Value | $5.64B | $183.83B |
Dividend Yield | 1.79% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.86, down 9.22% today, reflecting recent pressure despite beating earnings estimates in three consecutive quarters. The stock shows a bearish technical signal with key support at $55 and resistance at $59. Fundamentally, revenue has declined from $11.2B in 2022 to $8.6B in 2025, though net income turned positive at $44M in 2025 after a loss in 2024. Recent news highlights a brand campaign and expanded delivery partnership with OneRail.
The outlook is mixed; analyst consensus is a Hold with a $60.89 price target, suggesting modest upside. Opportunities include margin expansion and turnaround progress, but risks involve competitive pressures, volatile cash flows, and high P/E ratio. Investor sentiment is cautious amid declining revenue trends.
Gilead Sciences (GILD) trades at $136.36, up 3.88% today and 25.2% over the past year, showing strong momentum. The stock exhibits bullish technical signals with support at $128 and resistance at $136. Fundamentally, GILD maintains robust profitability with a 30.99% net margin and has beaten earnings estimates for three consecutive quarters. Recent FDA and EC approvals for Trodelvy's expanded use in metastatic triple-negative breast cancer provide significant growth catalysts.
GILD presents a compelling investment case with strong analyst support (65.5% buy ratings) and a $156.14 consensus price target offering 14.5% upside. Key risks include generic competition for dolutegravir and execution challenges in oncology growth. The company's solid cash flow generation and expanding product portfolio support continued shareholder value creation despite recent negative net cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
